Lilly’s tirzepatide is superior to Wegovy in head-to-head trial 

eAwazMedicine

TORONTO– Eli Lilly Canada today announced topline results from the SURMOUNT-5 Phase 3b open-label randomized clinical trial. Tirzepatide provided a 47% greater relative weight loss compared to Wegovy® (semaglutide). On average, tirzepatide led to a superior weight loss of 20.2% compared to 13.7% with Wegovy. At 72 weeks, tirzepatide was superior to Wegovy on both the primary endpoint and all five …

Health Canada approved 1st vaccine for RSV

eAwazMedicine

Ottawa – Health Canada has approved the first vaccine for respiratory syncytial virus (RSV) for adults age 60 and over. Manufacturer GSK says the federal agency has approved its new vaccine called Arexvy. Doctors have been calling for an RSV vaccine for seniors because although the virus is common, older people are much more likely to become severely ill and …